Clover Biopharmaceuticals has announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose (fourth vaccination dose) campaign targeting older adults, immunocompromised individuals and individuals with comorbidities.

Clover’s COVID-19 vaccine was authorised for emergency use in China in December 2022. Subsequently, the China National Health Commission formally announced its national immunisation plan for a second booster dose campaign and recommended prioritising specified vaccines that demonstrate broad neutralisation against Omicron, including Clover's, for use.

In a global Phase 2/3 clinical trial with over 30,000 participants across five countries, Clover’s COVID-19 vaccine achieved 100% efficacy against severe COVID-19 and hospitalisation caused by all strains of SARS-CoV-2 circulating during the trial.

In addition to Zhejiang province, Clover has started launch preparation activities in multiple strategically prioritized provinces and municipalities where it expects additional launches in Q1 2023. Further expansion within China will continue through 2023 based on production capacity and market dynamics. Outside of China, Clover is also prioritising additional regulatory submissions directly in select countries, primarily in Asia Pacific and Latin America, based on the potential to generate significant near-term revenue and impact via bilateral supply agreements.